Key points are not available for this paper at this time.
Pharmacogenomics, the study of how genetic variations influence drug response, has emerged as a cornerstone of personalized medicine, revolutionizing clinical practice across various medical specialties. This comprehensive review explores the applications, challenges, and prospects of pharmacogenomics in healthcare, with a particular focus on oncology. The integration of pharmacogenomic data into clinical decision-making processes enables healthcare providers to tailor drug therapy to individual patients based on their genetic makeup, thereby optimizing treatment outcomes while minimizing adverse effects. In oncology, pharmacogenomic testing plays a pivotal role in individualizing cancer therapy, predicting chemotherapy response, and selecting targeted therapies based on patients' genetic profiles. However, the widespread implementation of pharmacogenomics faces several challenges, including the need for robust evidence supporting its clinical utility, standardization of testing methodologies, and integration of genetic data into electronic health records. Despite these challenges, ongoing research efforts continue to advance our understanding of the genetic determinants of drug response, paving the way for personalized medicine to become an integral part of routine clinical practice. By addressing these challenges and leveraging technological advancements, pharmacogenomics holds the promise of enhancing patient care, improving treatment outcomes, and ultimately transforming the delivery of healthcare. Key words: Pharmacogenomics, personalized medicine, drug response, oncology, genetic variations, clinical practice
Geeth et al. (Sat,) studied this question.